MAY 19, 2020 10:11 AM PDT

Can Chinese Drug Cure COVID-19 Without Vaccine?

WRITTEN BY: Annie Lennon

Researchers at China’s Peking University have announced that they are developing a treatment capable of blocking COVID-19, without need for a vaccine. 

Their drug works giving patients 14 neutralizing antibodies that prevent the virus from infecting cells and spreading. Successfully tested on animal models, current results suggest that it may be able to significantly shorten recovery times. 

“The drug has been successful at the animal testing stage. When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500,” Sunney Xie, director of the university’s Beijing Advanced Innovation Center for Genomics. “The hope is these neutralised antibodies can become a specialised drug that would stop the pandemic,”

Plans to put the drug under clinical trials are now underway. As cases in China have dwindled in recent months, the researchers intend to conduct them on patients in Australia and further afield. Xie says that should all go to plan, the drug should be available for widespread use later this year; in time for a potential of a second wave during the winter. 

Beyond this treatment, China already has five vaccine candidates in human trials. However, due to their remaining 12-18 month timelines, drug companies and research labs alike are keen to find other avenues to curb the virus’s spread. 

Previously, scientists pointed out the potential benefits of injecting infected individuals with blood (and therefore, antibodies) from individuals who have already recovered from the virus. They hoped that the new antibodies would boost patients’ immunity and help them recover faster. Although showing ‘very good therapeutic effects’ among over 700 patients across China who received the therapy, due to limited supply of blood plasma, the treatment is not scalable. 

This is why Peking University’s antibody treatment may be a promising way to curb the spread of the COVID-19. Unlike blood transfusions, the 14 antibodies developed by the researchers can be mass-produced. Thus, should clinical trials show their effectiveness, they may become key in curbing the virus’s spread.  


Sources: The Star, Times Now News , NDTV

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUL 19, 2020
Neuroscience
Eating Fish May Protect Brain from Air Pollution
JUL 19, 2020
Eating Fish May Protect Brain from Air Pollution
Researchers have found that a diet high in omega-3 fatty acids may prevent neurodegeneration among older women living in ...
JUL 20, 2020
Neuroscience
Phantom-Limb Pain Reduced by Brain-Computer Interface
JUL 20, 2020
Phantom-Limb Pain Reduced by Brain-Computer Interface
Phantom-limb pain is a condition in which amputees feel like their amputated limb is still attached to their bodies. Whi ...
JUL 23, 2020
Cardiology
Protecting the Heart After a Heart Attack
JUL 23, 2020
Protecting the Heart After a Heart Attack
Cardiovascular disease accounts for thirty percent of mortalities around the world. These diseases start small and slowl ...
AUG 21, 2020
Immunology
Cancer Feels the STING
AUG 21, 2020
Cancer Feels the STING
Researchers have discovered a protein that can amplify immune reactions against tumors. The stimulator of interferon gen ...
AUG 11, 2020
Drug Discovery & Development
Engineering Drug-Producing Bacteria
AUG 11, 2020
Engineering Drug-Producing Bacteria
Researchers at Rice University worked to program a bacterium, Escherichia coli, to produce a synthetic "noncanonica ...
SEP 05, 2020
Drug Discovery & Development
Treatment in Cat Coronavirus Could Be Effective for Humans
SEP 05, 2020
Treatment in Cat Coronavirus Could Be Effective for Humans
Scientists at the University of Alberta are planning to launch clinical trials of a drug used to cure coronavirus in cat ...
Loading Comments...